ATE286398T1 - Desmethylolanzapine enthaltende zusammensetzungen und verfahren - Google Patents
Desmethylolanzapine enthaltende zusammensetzungen und verfahrenInfo
- Publication number
- ATE286398T1 ATE286398T1 AT99960547T AT99960547T ATE286398T1 AT E286398 T1 ATE286398 T1 AT E286398T1 AT 99960547 T AT99960547 T AT 99960547T AT 99960547 T AT99960547 T AT 99960547T AT E286398 T1 ATE286398 T1 AT E286398T1
- Authority
- AT
- Austria
- Prior art keywords
- desmethylolanzapine
- disorder
- compositions
- olanzapine
- treatment
- Prior art date
Links
- FHPIXVHJEIZKJW-UHFFFAOYSA-N 4'-N-desmethylolanzapine Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CCNCC1 FHPIXVHJEIZKJW-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 2
- 229960005017 olanzapine Drugs 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010017543 Fungal skin infection Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000016686 tic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10958498P | 1998-11-23 | 1998-11-23 | |
| PCT/US1999/027647 WO2000030650A1 (en) | 1998-11-23 | 1999-11-22 | Desmethylolanzapine compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE286398T1 true ATE286398T1 (de) | 2005-01-15 |
Family
ID=22328453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99960547T ATE286398T1 (de) | 1998-11-23 | 1999-11-22 | Desmethylolanzapine enthaltende zusammensetzungen und verfahren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6348455B1 (https=) |
| EP (1) | EP1133300B1 (https=) |
| JP (1) | JP2002530341A (https=) |
| AT (1) | ATE286398T1 (https=) |
| AU (1) | AU757973B2 (https=) |
| CA (1) | CA2351718A1 (https=) |
| DE (1) | DE69923081T2 (https=) |
| ES (1) | ES2237188T3 (https=) |
| PT (1) | PT1133300E (https=) |
| WO (1) | WO2000030650A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| PL199016B1 (pl) | 2002-06-20 | 2008-08-29 | Adamed Sp Z Oo | Sposób wytwarzania olanzapiny |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| CA2529857A1 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| KR100842694B1 (ko) | 2002-12-27 | 2008-07-01 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| US7763660B2 (en) * | 2003-02-05 | 2010-07-27 | The University Of Vermont And State Agricultural College | Inhibitors of Candida albicans |
| PL198589B1 (pl) | 2004-11-22 | 2008-06-30 | Adamed Sp Z Oo | Sposób wytwarzania N-demetyloolanzapiny |
| WO2006081327A2 (en) * | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| JP2010518023A (ja) * | 2007-02-01 | 2010-05-27 | アラン アイ． グリーン | ドーパミンＤ２受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα２受容体遮断剤との組み合わせ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115568A (en) | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US4590213A (en) * | 1983-04-08 | 1986-05-20 | Eli Lilly And Company | Anti-anxiety method |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| JPH11512705A (ja) | 1995-09-29 | 1999-11-02 | イーライ・リリー・アンド・カンパニー | チック症を処置する方法 |
| CA2240836A1 (en) | 1995-12-21 | 1997-07-03 | Pierre Van Tran | Method for treating dermatitis |
| HUP9903684A3 (en) | 1995-12-22 | 2001-12-28 | Lilly Co Eli | Use of olanzapine for the preparation of pharmaceutical compositions treating depression |
| HUP9903679A3 (en) | 1996-03-11 | 2001-10-29 | Lilly Co Eli | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder |
| KR19990087714A (ko) * | 1996-03-11 | 1999-12-27 | 피터 지. 스트링거 | 물질 남용의 치료 방법 |
| UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
| TR199801798T2 (xx) * | 1996-03-11 | 1998-12-21 | Eli Lilly And Company | Otizm tedavisi. |
| GB9615767D0 (en) | 1996-07-26 | 1996-09-04 | Smithkline Beecham Plc | Novel treatment |
-
1999
- 1999-11-22 CA CA002351718A patent/CA2351718A1/en not_active Abandoned
- 1999-11-22 EP EP99960547A patent/EP1133300B1/en not_active Expired - Lifetime
- 1999-11-22 ES ES99960547T patent/ES2237188T3/es not_active Expired - Lifetime
- 1999-11-22 JP JP2000583533A patent/JP2002530341A/ja not_active Withdrawn
- 1999-11-22 DE DE69923081T patent/DE69923081T2/de not_active Expired - Fee Related
- 1999-11-22 PT PT99960547T patent/PT1133300E/pt unknown
- 1999-11-22 US US09/444,590 patent/US6348455B1/en not_active Expired - Fee Related
- 1999-11-22 WO PCT/US1999/027647 patent/WO2000030650A1/en not_active Ceased
- 1999-11-22 AU AU17416/00A patent/AU757973B2/en not_active Ceased
- 1999-11-22 AT AT99960547T patent/ATE286398T1/de not_active IP Right Cessation
-
2001
- 2001-12-19 US US10/026,303 patent/US6468997B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002530341A (ja) | 2002-09-17 |
| ES2237188T3 (es) | 2005-07-16 |
| EP1133300B1 (en) | 2005-01-05 |
| CA2351718A1 (en) | 2000-06-02 |
| US20020082251A1 (en) | 2002-06-27 |
| DE69923081T2 (de) | 2005-12-08 |
| WO2000030650A1 (en) | 2000-06-02 |
| AU1741600A (en) | 2000-06-13 |
| PT1133300E (pt) | 2005-04-29 |
| EP1133300A1 (en) | 2001-09-19 |
| DE69923081D1 (de) | 2005-02-10 |
| US6468997B2 (en) | 2002-10-22 |
| AU757973B2 (en) | 2003-03-13 |
| US6348455B1 (en) | 2002-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE253364T1 (de) | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen | |
| ATE286398T1 (de) | Desmethylolanzapine enthaltende zusammensetzungen und verfahren | |
| PT751939E (pt) | Naftilamidas como agentes para o sistema nervoso central | |
| BRPI0402420A (pt) | Processos de toner | |
| DE69402352D1 (de) | Diamant/Kohlenstoff/Kohlenstoff-Verbundwerkstoff, verwendbar als integrales dielektrisches Kühlblech, und Verfahren zu seiner Herstellung | |
| DE69631065D1 (de) | Verbessertes mittel zur verringerung des fliesswiederstandes von schlamm | |
| DE602004029975D1 (de) | Geträgerter hybridmetallocenkatalysator, herstellungsverfahren dafür und verfahren zur herstellung von polyolefinen damit | |
| DE60001770D1 (de) | Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen | |
| BR9810762A (pt) | Processo de realização em uma base de dados de uma mudança de esquema | |
| DE69626393D1 (de) | Spezifische oligonukleotide für hepatitis b virus | |
| TR200101357T2 (tr) | Parkinson hastalığı, ADHD ve mikroadenomların tedavisi için ilaçlar. | |
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| BR0114983A (pt) | Derivados de amidoalquil-piperidina e amidoalquil-piperazina úteis para o tratamento de distúrbios do sistema nervoso | |
| DE69833645D1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| DE60231507D1 (de) | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten | |
| DE60025639D1 (de) | Substituierte diazepan | |
| ATE519859T1 (de) | Verfahren zur herstellung von ausgewählten intermolekularen quervernetzungen in nukleinsäuren und ihre verwendungen | |
| ATE363890T1 (de) | Kationische polymerisate und deren verwendung in kosmetischen formulierungen | |
| BR9910958A (pt) | Composição para cuidar de cabelo, e, processo para condicionar e conferir corpo ao cabelo | |
| DE69803909D1 (de) | Verfahren und Zwischenprodukte, die für die Herstellung von Antifolaten verwendbar sind | |
| Daube et al. | Translesion replication by DNA polymerase β is modulated by sequence context and stimulated by fork-like flap structures in DNA | |
| DE69810524D1 (de) | Polyethylenterephthalatharzzusammensetzung, geformtes Produkt und Modifikationsverfahren | |
| Mora | Mesillaros and Gringo Mexicans: The changing meanings of race, nation, and space in Southern New Mexico, 1848–1912 | |
| Laurent | The scent of music | |
| ATE291920T1 (de) | Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1133300 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |